TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

LATEST NEWS

Wall Street Stock Market
Play
JIM CRAMER

Resilient Bull: Cramer's 'Mad Money' Recap (Wednesday 1/8/20)

PRESS RELEASES

Apellis And Sobi: The New England Journal Of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan To Eculizumab For PNH

PRESS RELEASES

Apellis Announces Two New Publications From The Positive Phase 2 FILLY Study Evaluating Pegcetacoplan In Geographic Atrophy

PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Apellis Provides Update On APL-9 For Severe COVID-19

PRESS RELEASES

Apellis Pharmaceuticals To Present At Upcoming Investor Conferences

PRESS RELEASES

Apellis Pharmaceuticals To Hold Fourth Quarter And Full Year 2020 Earnings Conference Call On February 25, 2021

PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Apellis Pharmaceuticals To Host Investor Event On Geographic Atrophy On January 28, 2021

PRESS RELEASES

Apellis Pharmaceuticals To Present At The 39th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES

Apellis And Sobi Report Positive Top-line Results At 48 Weeks From The Phase 3 PEGASUS Study Of Pegcetacoplan In PNH

PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Apellis Pharmaceuticals To Present At The 2020 Evercore ISI HealthCONx Conference

PRESS RELEASES

Apellis And Sobi Announce First Patient Dosed In Potentially Registrational ALS Study Of Pegcetacoplan

PRESS RELEASES

Apellis Announces Late-Breaking Presentation Of Largest Retrospective Database Study In Geographic Atrophy (GA) At AAO 2020 Virtual

PRESS RELEASES

Apellis Pharmaceuticals To Present At Upcoming Investor Conferences

PRESS RELEASES

Apellis To Present New Data Supporting The Efficacy And Safety Of Pegcetacoplan In PNH At The American Society Of Hematology Annual Meeting

PRESS RELEASES

Apellis To Present Positive Results From The Phase 2 DISCOVERY Study Of Pegcetacoplan In C3 Glomerulopathy (C3G) At ASN Kidney Week

PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Apellis Initiates Registrational Programs Of Pegcetacoplan In Patients With C3G / IC-MPGN And ALS, Rare Diseases With High Unmet Need

PRESS RELEASES

Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression Of Early Disease In Patients With Geographic Atrophy (GA)

PRESS RELEASES

Apellis Pharmaceuticals To Present At Stifel's 2020 Immunology And Inflammation Virtual Summit

PRESS RELEASES

Apellis Announces Late-Breaking Presentation Of Targeted C3 Therapy Pegcetacoplan In Patients With Geographic Atrophy (GA) At EURETINA 2020

PRESS RELEASES

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Apellis Pharmaceuticals To Present At Upcoming Investor Conferences